Sentinel Lymph Node (SLN) - Comprehensive Overview

Definition

• Fitzpatrick's Dermatology, Vol. 1-2: "The SLN is per definition the first draining lymph node in the lymphatic draining system of the primary tumor."
• Bailey and Love's Surgery, 28th Ed.: "The sentinel node is the first node to which cancer cells are most likely to spread."

Historical Background

• The concept was introduced by Dr. Donald Morton in 1992 for cutaneous melanoma.
• Since then, sentinel lymph node biopsy (SLNB) has become standard of care for staging in melanoma, breast cancer, and many other solid tumors.
• Sabiston Textbook of Surgery: "Since it was introduced by Dr. Donald Morton in 1992, the SLN biopsy has become an indispensable tool in staging patients with cutaneous melanoma."

Clinical Importance

• SLNB is a staging and prognostic tool - it detects occult micrometastases in regional lymph nodes with much greater sensitivity than CT, PET scan, or ultrasound-guided fine-needle aspiration.
• The SLN status is the single most important prognostic factor in melanoma patients without clinical evidence of nodal metastases.
• A negative SLN spares the patient the morbidity of a full lymph node dissection.

Tumors Where SLNB is Used

Technique - How SLNB is Performed

Step 1 - Lymphoscintigraphy (Preoperative)

• Technetium-99m sulfur colloid (0.5 mCi same day; 2.5 mCi if injected the day before) is injected intradermally or peritumorally.
• In melanoma, injection is intradermal; in breast cancer, injections can be peritumoral, subareolar, or subdermal.
• A nuclear medicine scan maps which lymph node basin receives drainage.

Step 2 - Blue Dye Injection (Intraoperative)

• Isosulfan blue or methylene blue dye (3-5 mL) is injected in the operating room.
• Subdermal injection of blue dye is avoided - it can cause skin tattooing (isosulfan) or necrosis (methylene blue).
• Patients are warned: urine may turn blue, and there is a 1/10,000 risk of allergic reaction to isosulfan blue.

Step 3 - Intraoperative Detection

• A hand-held gamma probe (counter) detects the radioactive colloid transcutaneously to guide incision placement.
• Blue lymphatic channels are followed to the SLN.
• A node is considered the SLN if it is blue-stained, has high radioactivity counts (typically >10x background), or is palpably hard.
• The combination of isotope + blue dye is more accurate than either alone.

Step 4 - Histologic Analysis

• SLN is sent for serial sectioning with H&E staining.
• In melanoma, immunohistochemistry (IHC) is added: S100, HMB-45, and/or Melan-A.
• IHC upstages 10-20% of patients who would otherwise be considered node-negative.
• Even single melanoma cells on IHC defines the node as SLN-positive (N1a).

Indications by Tumor

Melanoma (AJCC Guidance)

• Recommended: all T2+ melanomas (>1.0 mm Breslow thickness)
• Consider: T1b melanomas (0.8-1.0 mm, or with ulceration), or <0.8 mm with high mitotic rate (≥1/mm²), lymphovascular invasion, or young age
• Not routinely recommended: thin T1a melanomas without adverse features

• < 1 mm: ~5.6% (rises to 19.5% if <40 years old, 0.75-1 mm, ulcerated, or with mitoses)
• 1-4 mm: ~25.2%

• 4 mm: ~50%

Breast Cancer

• Standard for clinically node-negative (N0) patients with early breast cancer (T1, T2, and even T3 N0).
• Accuracy: sensitivity 93%, false-negative rate 7%, negative predictive value 94%, overall accuracy 95% (Tan et al meta-analysis, 449 cases).
• Contraindications: inflammatory breast cancer, biopsy-proven axillary metastasis, DCIS without mastectomy, prior axillary surgery.
• Safe in pregnancy when performed with radioisotope alone (without blue dye).

Oral Cavity SCC (Head & Neck)

• Used in cN0 patients (T1/T2) to detect occult metastases and guide need for formal neck dissection.
• Can reveal unexpected contralateral lymph node drainage.
• False-negative rate: ~14%.
• Evidence supports elective neck dissection over "watch and wait" for T1/T2 oral SCC - SLNB identifies which patients truly need it.

Efficacy Metrics

When SLNB Should NOT Be Done

• After wide local excision (WLE) in areas with surgically altered lymphatic drainage (reduced accuracy in melanoma)
• When performed after local skin flap (injection site is away from true primary)
• Inflammatory breast cancer
• Biopsy-proven nodal metastasis
• DCIS without mastectomy
• Prior axillary surgery

Landmark Trial: MSLT-I (Morton et al, 2006)

• 1,269 clinically node-negative melanoma patients (1.2-3.5 mm depth)
• Randomized to: wide excision + nodal basin observation vs. wide excision + SLNB
• Patients with a positive SLN underwent immediate completion lymphadenectomy
• Demonstrated that SLNB with early completion lymphadenectomy improved disease-free survival vs. delayed lymphadenectomy

Recent Evidence (2024-2026)

Note: ICG fluorescence is an emerging technique that may complement or replace standard isotope/blue dye mapping in some settings, according to recent evidence.

Summary